Curcumin Knee Pain Randomized Trial: What the Evidence Says

Quick Answer

Curcumin Knee Pain Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Osteoarthritis (OA) is the most common musculoskeletal disease globally, which leads to significant disability arising from reduced joint mobility, increased functional burden, and reduced quality of life. [Lopresti Adrian L. (2026); evidence level 2]
• In a recent meta-analysis, it was concluded that, based on 23 studies and 2,175 patients with knee OA, compared with placebo, oral curcumin reduced self-reported pain as measured by the visual analogue scale and the Western Ontario and McMaster Universities Arthritis Index. [Lopresti Adrian L. (2026); evidence level 2]
• Arthritis constitutes a major global health burden and remains one of the leading causes of chronic pain, disability, and reduced quality of life worldwide. [Toumi Hechmi (2026); evidence level 3]
• OA is primarily a degenerative disease associated with aging and mechanical stress, whereas RA is an autoimmune disorder characterized by systemic inflammation and synovial hyperplasia. [Toumi Hechmi (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For curcumin knee pain randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Lopresti Adrian L. (2026). The effect of a topical curcumin formulation (VAS-101) on knee pain in adults with knee osteoarthritis: a randomised, double-blind, placebo-controlled study. DOI: 10.3389/fpain.2026.1789088. PMCID: PMC13079332. PMID: 41994034. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13079332/
• Toumi Hechmi (2026). Curcumin in Arthritis: Molecular Mechanisms, Preclinical Evidence, and Clinical Applications. DOI: 10.3390/ijms27114894. PMCID: PMC13256076. PMID: 42278424. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13256076/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.